Lipid- and Carrier-Free Drug Delivery Compositions

Tunable, non-lipid-based compositions for carrier-free delivery of therapeutic biopolymers such as RNA.

 

Background:

 

Membrane-less organelles (MLOs), which are fluid compartments formed from proteins and RNA through liquid-liquid phase separation, serve important biological functions within cells.  In an effort to better understand the forces driving their formation and alteration, a variety of hollow, lipid-free, vesicle-like compositions and methods for their preparation have been developed.

 

Technology Overview:

 

This invention provides polyionic vesicles comprising a layer made up of oppositely charged (bio)polymers.  These lipid-free vesicles are referred to as membrane-like nucleoprotein assemblies (MNAs).  MNAs exhibit structural and functional similarities to liposomes, including an ability to selectively encapsulate biomolecules.  More generally, these highly tunable vesicles, which comprise a rim layer that defines an interior volume, exhibit molecular ordering, size-dependent permeability, selective encapsulation and complex surface topology.  These MNAs may be used for drug delivery and/or as tunable, stimuli-responsive release/trapping systems.  Drug delivery applications can employ carrier-free vesicles, wherein a therapeutic biopolymer (e.g. RNA, DNA, protein, etc.) is provided as a component of the rim structure, and/or drug-loaded vesicles, wherein therapeutic cargo is present within the lumen.  Beyond therapeutics, agricultural biotechnology applications, including the release of insecticides and/or pesticides, are also possible through the use of these novel vesicles.

 

Publication Link: bioRxiv 2020

              

Advantages:

 

These MNAs can be prepared without the use of organic solvents, unlike liposomes.  In drug-delivery applications, these compositions enable carrier-free delivery of therapeutic biopolymers, including but not limited to RNA.

 

Applications:

 

•       Drug delivery

•       Agricultural biotechnology

 

Intellectual Property Summary:

US Provisional Patent Application 62/958,039 filed January 7, 2020.

 

Stage of Development: In vitro demonstration.

 

Licensing Status: Available for licensing or collaboration.

 

Patent Information:
Technology/Start-up ID: